Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 12/20 | 0.60 |
| ▸ | ATXN2 | Q99700 | 6/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 3/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15551709 | 0.89 | ENPP2 (0.78) | ENPP2ATXN2KCNH2 | |
| SCHEMBL18464187 | 0.85 | ENPP2 (0.63) | ENPP2ATXN2KCNH2 | |
| SCHEMBL18464309 | 0.84 | ENPP2 (0.60) | ENPP2ATXN2PARP1ROCK2ROCK1 | |
| SCHEMBL118338 | 0.82 | ENPP2 (0.52) | ENPP2ATXN2 | |
| SCHEMBL16252473 | 0.81 | ENPP2 (0.57) | ENPP2ATXN2KCNH2 | |
| SCHEMBL16252471 | 0.80 | ENPP2 (0.47) | ENPP2ATXN2DRD4 | |
| SCHEMBL21323059 | 0.79 | ENPP2 (0.52) | ENPP2ATXN2KCNH2 | |
| SCHEMBL16962855 | 0.79 | ENPP2 (0.52) | ENPP2ATXN2KCNH2 | |
| SCHEMBL15552088 | 0.78 | ENPP2 (0.77) | ENPP2ATXN2 | |
| SCHEMBL146674 | 0.78 | SLC6A5 (0.50) | ENPP2ATXN2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | ENPP2 1/4885ATXN2 500/4885KCNH2 3381/4885 |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | ENPP2 1/4885ATXN2 280/4885KCNH2 3175/4885 |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | ENPP2, DAPK1, DAPK2 | ENPP2 1/4885ATXN2 500/4885KCNH2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.